Lonza Group (LONN) Stock Overview
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LONN Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Lonza Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 571.00 |
| 52 Week High | CHF 616.00 |
| 52 Week Low | CHF 467.80 |
| Beta | 0.80 |
| 1 Month Change | -0.17% |
| 3 Month Change | 1.17% |
| 1 Year Change | 4.05% |
| 3 Year Change | 10.96% |
| 5 Year Change | 3.11% |
| Change since IPO | 522.00% |
Recent News & Updates
Here's Why Lonza Group (VTX:LONN) Has A Meaningful Debt Burden
Aug 20
Lonza Group AG (VTX:LONN) Not Flying Under The Radar
May 31Is It Too Late To Consider Buying Lonza Group AG (VTX:LONN)?
Apr 25Recent updates
Here's Why Lonza Group (VTX:LONN) Has A Meaningful Debt Burden
Aug 20Lonza Group AG (VTX:LONN) Not Flying Under The Radar
May 31Is It Too Late To Consider Buying Lonza Group AG (VTX:LONN)?
Apr 25Is Lonza Group (VTX:LONN) Using Too Much Debt?
Mar 20Why We're Not Concerned About Lonza Group AG's (VTX:LONN) Share Price
Feb 27There May Be Reason For Hope In Lonza Group's (VTX:LONN) Disappointing Earnings
Feb 06
CDMO Focus And Vacaville Acquisition To Drive Operational Improvements By 2025
Focus on CDMO business and Vacaville acquisition to drive revenue growth and boost sales.Market Participants Recognise Lonza Group AG's (VTX:LONN) Earnings
Nov 29Is Lonza Group (VTX:LONN) Using Too Much Debt?
Nov 08Shareholder Returns
| LONN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | -0.3% | -1.4% | -0.5% |
| 1Y | 4.0% | -5.5% | -1.7% |
Return vs Industry: LONN exceeded the Swiss Life Sciences industry which returned -5.9% over the past year.
Return vs Market: LONN exceeded the Swiss Market which returned -1.7% over the past year.
Price Volatility
| LONN volatility | |
|---|---|
| LONN Average Weekly Movement | 2.3% |
| Life Sciences Industry Average Movement | 4.7% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: LONN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: LONN's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 19,299 | Wolfgang Wienand | www.lonza.com |
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.
Lonza Group AG Fundamentals Summary
| LONN fundamental statistics | |
|---|---|
| Market cap | CHF 40.33b |
| Earnings (TTM) | CHF 733.00m |
| Revenue (TTM) | CHF 7.09b |
Is LONN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LONN income statement (TTM) | |
|---|---|
| Revenue | CHF 7.09b |
| Cost of Revenue | CHF 4.51b |
| Gross Profit | CHF 2.59b |
| Other Expenses | CHF 1.85b |
| Earnings | CHF 733.00m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.38 |
| Gross Margin | 36.47% |
| Net Profit Margin | 10.33% |
| Debt/Equity Ratio | 53.2% |
How did LONN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/01 13:47 |
| End of Day Share Price | 2025/09/01 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lonza Group AG is covered by 54 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |